Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pediatric Transplants

Hematopoietic cell transplantation for Chediak–Higashi syndrome


We reviewed outcomes after allogeneic hematopoietic cell transplantation (HCT) in 35 children with Chediak–Higashi syndrome (CHS). Twenty-two patients had a history of the life-threatening accelerated phase of CHS before HCT and 11 were in accelerated phase at transplantation. Thirteen patients received their allograft from an human leukocyte antigen (HLA)-matched sibling, 10 from an alternative related donor and 12 from an unrelated donor. Eleven recipients of HLA-matched sibling donor, three recipients of alternative related donor and eight recipients of unrelated donor HCT are alive. With a median follow-up of 6.5 years, the 5-year probability of overall survival is 62%. Mortality was highest in those with accelerated phase disease at transplantation and after alternative related donor HCT. Only four of 11 patients with active disease at transplantation are alive. Seven recipients of alternative related donor HCT had active disease at transplantation and this may have influenced the poor outcome in this group. Although numbers are limited, HCT appears to be effective therapy for correcting and preventing hematologic and immunologic complications of CHS, and an unrelated donor may be a suitable alternative for patients without an HLA-matched sibling. Early referral and transplantation in remission after accelerated phase disease may improve disease-free survival.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Barak Y, Nir E . Chediak–Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9: 42–55.

    Article  CAS  Google Scholar 

  2. Pettit RE, Berdal KG . Chediak–Higashi syndrome. Neurologic appearance. Arch Neurol 1984; 41: 1001–1002.

    Article  CAS  Google Scholar 

  3. Grossi CE, Crist WM, Abo T, Velardi A, Cooper MD . Expression of the Chediak–Higashi lysosomal abnormality in human peripheral blood lymphocyte subpopulations. Blood 1985; 65: 837–844.

    CAS  PubMed  Google Scholar 

  4. Certain S, Barrat F, Pastural E, Le Deist F, Goyo-Rivas J, Jabado N et al. Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak–Higashi syndrome. Blood 2000; 95: 979–983.

    CAS  PubMed  Google Scholar 

  5. Zarzour W, Kleta R, Frangoul H, Suwannarat P, Jeong A, Kim SY et al. Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak–Higashi syndrome. Mol Genet Metab 2005; 85: 125–132.

    Article  CAS  Google Scholar 

  6. Davis WC, Douglas SD . Defective granule formation and function in the Chediak–Higashi syndrome in man and animals. Semin Hematol 1972; 9: 431–450.

    CAS  PubMed  Google Scholar 

  7. Abo T, Roder JC, Abo W, Cooper MD, Balch CM . Natural killer (HNK-1+) cells in Chediak–Higashi patients are present in normal numbers but are abnormal in function and morphology. J Clin Invest 1982; 70: 193–197.

    Article  CAS  Google Scholar 

  8. Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME et al. The accelerated phase of Chediak–Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56: 524–530.

    Article  CAS  Google Scholar 

  9. Aslan Y, Erduran E, Gedik Y, Mocan H, Yildiran A . The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chediak–Higashi syndrome. Acta Haematol 1996; 96: 105–107.

    Article  CAS  Google Scholar 

  10. Fukuda M, Morimoto T, Ishida Y, Suzuki Y, Murakami Y, Kida K et al. Improvement of peripheral neuropathy with oral prednisolone in Chediak–Higashi syndrome. Eur J Pediatr 2000; 159: 300–301.

    Article  CAS  Google Scholar 

  11. Filipovich AH, Shapiro RS, Ramsay NK, Kim T, Blazar B, Kersey J et al. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. Blood 1992; 80: 270–276.

    CAS  PubMed  Google Scholar 

  12. Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency. Blood 1994; 83: 1149–1154.

    CAS  PubMed  Google Scholar 

  13. Diamond HR, Souza MH, Silva ML, Tabak DG, Ferman S, M-Silva VM et al. Natural killer cell activity in a patient with Chediak–Higashi syndrome submitted to bone marrow transplantation. Pediatr Hematol Oncol 1995; 12: 399–402.

    Article  CAS  Google Scholar 

  14. Mottonen M, Lanning M, Saarinen UM . Allogeneic bone marrow transplantation in Chediak–Higashi syndrome. Pediatr Hematol Oncol 1995; 12: 55–59.

    Article  CAS  Google Scholar 

  15. Haddad E, Le Deist F, Blanche S, Benkerrou M, Rohrlich P, Vilmer E et al. Treatment of Chediak–Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases. Blood 1995; 85: 3328–3333.

    CAS  PubMed  Google Scholar 

  16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  17. Flowers ME, Kansu E, Sullivan KM . Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091–1112, viii-ix.

    Article  CAS  Google Scholar 

  18. Klein JP, Moeschberger ML . Survival Analysis: Techniques of Censored and Truncated Data. Springer-Verlag: Berlin, 2003.

    Google Scholar 

  19. Tardieu M, Lacroix C, Neven B, Bordigoni P, de Saint Basile G, Blanche S et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak–Higashi syndrome. Blood 2005; 106: 40–42.

    Article  CAS  Google Scholar 

Download references


This study was supported by Public Health Service Grant U24-CA76518-08 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute.

Author information

Authors and Affiliations


Corresponding author

Correspondence to A H Filipovich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eapen, M., DeLaat, C., Baker, K. et al. Hematopoietic cell transplantation for Chediak–Higashi syndrome. Bone Marrow Transplant 39, 411–415 (2007).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links